{
    "clinical_study": {
        "@rank": "35047", 
        "arm_group": {
            "arm_group_label": "VITAROS", 
            "arm_group_type": "Experimental", 
            "description": "VITAROS (Alprostadil) 330 ug PRN (as needed) transdermal topical 4-8 weeks"
        }, 
        "brief_summary": {
            "textblock": "A Phase 4 clinical trial that is open, with no blinding of subjects or randomization of\n      treatment. Patients with erectile problems will be given the approved drug Vitaros to treat\n      their condition. They will be given forms and questionnaires to complete. The information\n      collected will be used to assess the effectiveness, safety and the satisfaction levels with\n      this drug."
        }, 
        "brief_title": "Efficacy, Safety and Satisfaction of VITAROS (Transdermal Topical Alprostadil) in Men With Erectile Dysfunction", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Erectile Dysfunction", 
        "condition_browse": {
            "mesh_term": "Erectile Dysfunction"
        }, 
        "detailed_description": {
            "textblock": "Transdermal topical alprostadil has been approved for use in Canada as a treatment for\n      erectile dysfunction. However, as this form of treatment is new, and Canada is the first\n      country in the world to approve its use. There are very few published articles in literature\n      to evaluate its clinical acceptance. By performing a Phase 4, Open-Label, Non-Randomized,\n      Clinical Trial to Evaluate the Efficacy, Safety and Satisfaction of VITAROS (transdermal\n      topical alprostadil) in Men with Erectile Dysfunction, this study can improve understanding\n      of this method of treatment as compared to conventional treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18y rs old and above\n\n          -  Has mild-to-moderate erectile dysfunction\n\n          -  Currently or previous treated for erectile dysfunction using PDE5 inhibitors, vacuum\n             erection devices (VED), intra-cavernosal injections (ICI) and medical urethral system\n             for erection (MUSE).\n\n          -  Sexually active\n\n          -  Has a regular sexual partner\n\n        Exclusion Criteria:\n\n          -  Known allergy to alprostadil\n\n          -  Unable to provide own informed consent\n\n          -  Unable to understand and complete a questionnaire in English\n\n          -  Unable to return for a post-treatment clinic evaluation\n\n          -  Regular sexual partner is unable to understand and complete a questionnaire in\n             English\n\n          -  Sexual partner is a pregnant or lactating female"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 7, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01776320", 
            "org_study_id": "103243"
        }, 
        "intervention": {
            "arm_group_label": "VITAROS", 
            "description": "One unit of Vitaros(330ug of Alprostadil)once a week or once every two weeks for four or eight weeks.", 
            "intervention_name": "Alprostadil", 
            "intervention_type": "Drug", 
            "other_name": "VITAROS"
        }, 
        "intervention_browse": {
            "mesh_term": "Alprostadil"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Erectile Dysfunction", 
            "Topical Alprostadil"
        ], 
        "lastchanged_date": "March 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "Canada", 
                    "state": "Ontario", 
                    "zip": "N6A 4V2"
                }, 
                "name": "St. Joseph's Health Care London"
            }
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 4, Open-Label, Non-Randomized, Clinical Trial to Evaluate the Efficacy, Safety and Satisfaction of VITAROS (Transdermal Topical Alprostadil) in Men With Erectile Dysfunction.", 
        "overall_official": {
            "affiliation": "St.Joseph's Health Care", 
            "last_name": "Gerald Brock, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "Canada: Ethics Review Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The efficacy of Topical alprostadil in the treatment of erectile dysfunction as measured by IIEF scores.", 
            "safety_issue": "Yes", 
            "time_frame": "4 - 8weeks"
        }, 
        "reference": {
            "PMID": "23170913", 
            "citation": "Costa P, Potempa AJ. Intraurethral alprostadil for erectile dysfunction: a review of the literature. Drugs. 2012 Dec 3;72(17):2243-54. doi: 10.2165/11641380-000000000-00000."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01776320"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Lawson Health Research Institute", 
            "investigator_full_name": "Gerald Brock", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Evaluate patient satisfaction of transdermal topical alprostadil when compared to patient's most current mode of therapy for erectile dysfunction.", 
            "safety_issue": "No", 
            "time_frame": "4 - 8 weeks"
        }, 
        "source": "Lawson Health Research Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Lawson Health Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014", 
        "why_stopped": "No medication"
    }
}